GSK’s Prices Breo On Par With Advair For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
The wholesale acquisition cost of GlaxoSmithKline’s once-daily COPD medication Breo is the same as Advair, reflecting the high reimbursement hurdle for new respiratory medicines.
You may also be interested in...
Breo Launch Timing Slips But No “Drama,” GSK’s Witty Says
The once-daily COPD medication Breo is an important launch for GSK, and the company has pushed back the timing by a few weeks, potentially into the fourth quarter, to make sure it is “nailed,” CEO Witty says during the company’s second quarter call. Nonetheless, Breo may be experiencing more pushback from payers than GSK expected.
Breo Inverts Traditional Path To COPD Indication For LABA Combinations
GlaxoSmithKline’s NDA for Breo Ellipta sought a COPD indication without prior approval of the combination product or its individual inhaled corticosteroid and long-acting beta agonist components in asthma. A broad development program with extensive dose finding won over a skeptical FDA.
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.